Daclizumab is a humanized monoclonal antibody that binds to CD25, a high affinity receptor that is expressed at low levels on resting T cells, which are a type of immune cell, and at high levels on T cells that can become activated in response to autoimmune conditions such as MS.

Daclizumab is currently in clinical development for the treatment of multiple sclerosis (MS).

We have a worldwide strategic development collaboration for daclizumab with Biogen Idec in which we share development costs and commercial rights in MS and in indications other than respiratory and transplant. We wholly own the rights for daclizumab in respiratory and transplant indications, which are not subject to our collaboration agreement with Biogen Idec.

CHOICE Presentation